Where Denali Therapeutics Stands With Analysts
Over the past 3 months, 8 analysts have published their opinion on Denali Therapeutics (NASDAQ:DNLI) stock. These analysts…
Denali Therapeutics Reveals New Interim Data From Early-Stage Hunter Syndrome Study
Denali Therapeutics Inc (NASDAQ:DNLI) announced new interim results from the ongoing open-label, single-arm Phase 1/2 study of DNL310 in children with…
HC Wainwright & Co. Reiterates Buy on Denali Therapeutics, Maintains $105 Price Target
HC Wainwright & Co. analyst Andrew Fein reiterates Denali Therapeutics (NASDAQ:DNLI) with a Buy and maintains $105 price target.
Expert Ratings for Denali Therapeutics
Over the past 3 months, 4 analysts have published their opinion on Denali Therapeutics (NASDAQ:DNLI) stock. These analysts…
SVB Leerink Initiates Coverage On Denali Therapeutics with Outperform Rating, Announces Price Target of $50
SVB Leerink analyst Marc Goodman initiates coverage on Denali Therapeutics (NASDAQ:DNLI) with a Outperform rating and announces Price Target of $50.
Morgan Stanley Maintains Overweight on Denali Therapeutics, Lowers Price Target to $60
Morgan Stanley analyst Matthew Harrison maintains Denali Therapeutics (NASDAQ:DNLI) with a Overweight and lowers the price target from $67 to $60.
Denali Therapeutics Late Wednesday Announces Pricing Of $275M Public Offering Of 10,377,359 Shares Of Common Stock For $26.50 Per Share
Denali Therapeutics Inc. (NASDAQ:DNLI) today announced the pricing of its underwritten public offering of 10,377,359 shares of its common stock at a price to the public of $26.50 per share. All of the shares
Denali Therapeutics Announces Proposed Offering Of $250M Of Common Stock
Denali Therapeutics Inc. (NASDAQ:DNLI) today announced that it intends to offer and sell $250 million of shares of its common stock in an underwritten public offering. In addition, Denali Therapeutics intends
Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday
Gainers
PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The trial met its primary endpoint.
Netflix, Biogen And Other Big Gainers From Wednesday
U.S. stocks closed higher with the Dow Jones surging more than 500 points on Wednesday. Here is the list of some big stocks recording gains in the previous session.